Our Lab

Florian Grebien
Principal investigator

Florian Grebien did his PhD jointly supervised by Ernst Müllner of the Medical University Vienna and Hartmut Beug of the Research Institute for Molecular Pathology (IMP) in Vienna. For his post-doctoral research he joined the team of Giulio Superti-Furga at the Research Center for Molecular Medicine (CeMM), Vienna. From 2014 to 2018, he was a Principal Investigator and group leader at the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) in Vienna. In January 2018, he was appointed Professor and head of the institute for Medical Biochemistry at the University of Veterinary Medicine Vienna.

Florian Grebien’s research focuses on acute myeloid leukemia (AML), a cancer of white blood cells that is characterized by the rapid growth of abnormal myeloid cells that accumulate in the bone marrow and interfere with the production of normal blood cells. The Grebien laboratory aims to contribute to a better understanding of the molecular mechanisms of leukemia development. We study cellular and molecular effects of leukemia-associated oncoproteins through the development and use of novel tools, including cell culture and mouse models, Next Generation Sequencing, Mass Spectrometry and primary patient samples.

Manuela Thullner
Secretary

E-Mail

Melanie Allram
PhD student

“I am investigating NUP98-fusion proteins and their interaction partners in the context of biomolecular condensates as drivers for leukemogenic gene expression.”

E-Mail

Jessica Ebner
PhD student

“I aim to investigate new therapeutic targets in acute myeloid leukemia to improve targeted therapy. I am currently working on drug synergies and synthetic lethal interactions in acute myeloid leukemia.”

E-Mail | Twitter | ORCID

Thomas Eder
PostDoc

“As bioinformatician I have a special interest in cutting edge NGS technologies, the resulting data and its applications as well as tool development. My research focuses on normalization methods and techniques used for differential gene expression and differential ChIP-seq.”

E-Mail | Twitter | ORCID

Elizabeth Heyes
PostDoc

“I am studying cooperative effects of frequently co-occurring mutations in AML. I am using CRISPR/Cas9 to generate novel in vitro and in vivo models, which I analyze via state-of-the-art NGS technologies”

E-Mail | Twitter | ORCID

Gabriele Manhart
Technician (and artist)

“Eager to acquire experience in state of the art techniques and gain a profound background in cancer research, specifically acute myeloid leukaemia, I am participating in various projects and help wherever needed.”

E-Mail

Martin Piontek
MSc student

“I am investigating the role of ABC transporters in different AML cell lines in combination with newly established targeted therapies.”

E-Mail

Ludovica Proietti
PhD student

“I am characterizing the role of mutated CEBPA in AML, applying technologies such as CRISPR/Cas9-based screening.”

E-Mail | Twitter

Torben Redmer
PostDoc

“The focus of our research is the identification of mechanisms and drivers of melanoma metastasis, particularly metastasis to the brain, applying NGS, methylome analyses of patient-derived melanoma brain metastases and cellular model systems as well as confocal imaging of tumors and in vivo (mouse model) and semi-in vivo (organotypic brain-slice culture) approaches.”

E-Mail

Selina Tröster
PhD student

“My aim is to establish novel models for the study of NUP98-fusion proteins to investigate cellular processes important for leukemia caused by these fusion proteins.”

E-Mail | Twitter | ORCID

Anna Vidal
PhD student

“My work aims to understand the complexity of melanoma brain metastasis formation. I use CRISPRa/i systems on patient derived melanoma cell lines to study the interaction with astrocytes and the role of CD271.”

E-Mail